• Targos projectmanagement Team and Targos building

  • Targos Lab Team

  • Targos Logistics Team

  • Targos Advance Team

  • Targos Study Office Team

  • Targos employees and Targos building

  • Expert Training by Targos

  • Expert Training - microscope room

Targos - A Leader in Biomarker Services for more than 10 years

Targos GmbH building and staff 2015

Targos core service business is to provide highly standardized development and application of clinical biomarkers for the international pharmaceutical and diagnostic industry.

The company has supported more than 400 international clinical trials since 2005, which have led to the successful approval of several targeted therapies and IVDs for our customers.

The expert team of on-site clinical pathologists operates in a professional environment of project management, logistics, data and quality management. Targos also supports the introduction of new Companion Diagnostic assays into the market.

Targos is a fully GCP-compliant central laboratory that is inspected by the U.S. Food and Drug Administration (FDA). Since 2014 Targos Molecular Pathology GmbH is accredited by the College of American Pathologists and the US-CLIA program.

Targos News

Cancer of unknown primary (CUP)

Conference Announcement

Targos together with his partner Roche is organizing an international meeting:

Cancer of unknown primary (CUP).

If you like to "Make the unknown known" join the educational meeting for oncologists and pathologists about CUP at 28th - 29th of June 2019 in Zurich.

Attendance is only possible for Oncologists and Pathologists. 


»Click here to participate

multiplex IHC - click to enlarge
multiplex IHC

June 23, 2019

Targos Joins Definiens Panel Discussion at WIN Symposium in Paris

Artificial Intelligence (AI) to Support Patient Profiling in Precision Oncology

Definiens & Targos collaborate to offer AI-powered biomarker analysis & multiplex IHC end-to-end solutions - from assay development to confident decision making

Through this partnership, you'll be able to take advantage of co-validated custom and standardized multiplex immunohistochemistry (IHC) solutions. The targeted biomarker spatial and advanced analytics are provided through an interactive online shareable web portal with live status updates.Furthermore, you'll be guided by a team of data and translational scientists, clinical pathologists, assay development, image analysis, and regulatory experts from the exploratory phase to clinical phase - full end-to-end service offerings.

“Providing our customers with the finest, high-quality biomarker services/analyses, and making use of innovative multiplexing immunohistological technologies to solve pressing problems in precision medicine guided targeted and immunotherapy is the core of this collaboration,” said Prof. Josef Rüschoff, MD, Chief Medical Officer of Targos. 

»Learn more here